3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Interventions
Rituximab
56
Cyclophosphamide
39
fludarabine
23
fludarabine phosphate
18
Peripheral Blood Stem Cell Transplantation
17
Lenalidomide
14
Melphalan
13
Etoposide
12
venetoclax
11
Whole-Body Irradiation
11
Mycophenolic Acid
11
obinutuzumab
10
Vincristine
10
Prednisone
10
Bendamustine Hydrochloride
10
Doxorubicin
9
Cytarabine
9
Cyclosporine
9
Bortezomib
9
Filgrastim
8
pembrolizumab
7
Nivolumab
7
Gemcitabine
7
Busulfan
7
acalabrutinib
6
Tacrolimus
6
Interleukin-2
6
Dexamethasone
6
Carmustine
6
Alemtuzumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Non-Hodgkin
×
Automobiles
×
Clear all
NCT03938987
2026-02-09
ACIT001/EXC002
University of Alberta
Phase 1/2
Recruiting
63 enrolled